PS-1145 is a potent and selective inhibitor of IκB kinase β (IKKβ), a key enzyme in the NF-κB signaling pathway. This pathway plays a central role in regulating the expression of genes involved in inflammation, immune response, and cell survival. By inhibiting IKKβ, PS-1145 effectively suppresses NF-κB activation, making it a valuable tool in research focused on inflammatory diseases, autoimmune disorders, and cancer.

In preclinical studies, PS-1145 has demonstrated anti-inflammatory effects by reducing the production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. It has also shown potential in sensitizing cancer cells to apoptosis, particularly in tumor types where constitutive NF-κB activity promotes cell survival and resistance to therapy. Due to its ability to modulate immune and inflammatory responses, PS-1145 is widely used in experimental models to dissect the role of NF-κB in disease progression and to evaluate therapeutic strategies targeting this pathway.

Its application remains primarily in the research domain, where it serves as a pharmacological probe to study signaling mechanisms and validate IKKβ as a drug target.